TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04333433

Intervention type: DEVICE
Intervention: PRESERFLO® MicroShunt
Description: Device surgically implanted

Intervention type: PROCEDURE
Intervention: Trabeculectomy
Description: The procedure involves removal of a small portion of the trabecular meshwork and adjacent scleral tissue. Aqueous humor then drains into the subconjunctival space, creating a bleb on the external part of the eye, where it diffuses away.
Study: NCT03070457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early discharge
Description: Patients randomised to early discharge or not

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional protocol
Description: Discharge as usually done 48-72 hours after surgery
Study: NCT01926379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination intervention components
Description: The CIP will contain programmatic, structural, and psychosocial components, including:~1. use of a clinical algorithm by providers;~2. identification of HIV-infected family members eligible for IPT, using an ICAP-developed family care enrollment form (ICAP - International Center for AIDS Care and Treatment Programs);~3. review of monitoring data on IPT initiation and adherence during monthly multidisciplinary team meetings;~4. reimbursement of transportation costs for monthly clinic visits; and~5. real-time adherence support using IVR via mobile phones and trained Peer Educators.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid Prevention Therapy
Description: Standard of care involves Isoniazid Prevention Therapy (IPT) - the administration of Isoniazid (INH) to individuals with latent infection with M. tuberculosis in order to prevent progression to active TB disease.

Intervention type: DRUG
Group type: OTHER
Intervention: Isoniazid Prevention Therapy
Description: Standard of care involves Isoniazid Prevention Therapy (IPT) - the administration of Isoniazid (INH) to individuals with latent infection with M. tuberculosis in order to prevent progression to active TB disease.
Study: NCT03207828

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation
Description: The Brief Behavioral Activation Treatment for Depression (Lejuez, Hopko, Acierno, Daughters, \& Pagoto, 2011; Lejuez, Hopko, LePage, Hopko, and McNeil; 2001) will be used. It aims are (1) to increase engagement with activities associated with pleasure or mastery experiences; (2) decrease engagement with activities that maintain or increase the risk of depression; (3) and remove the barriers that limit the access to gratification. The sessions of therapy are well structured and described in its manual. The protocol was originally designed to be applied individually. However, for the present research, it will be adjusted to be applied in group sessions (5-8 participants). Materials will be also adjusted to be use with Chilean population. Treatment core aspects will not be altered. The treatment will last 10 sessions over two months. Two psychologist trained in behavioral activation will lead the sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Participants will be attended by a Medical Doctor that has a high level of expertise in fibromyalgia (rheumatologist or chronic pain specialist) at the Red Salud Christus, the most important private medical care network in Chile. In this clinic the protocol for the treatment of fibromyalgia includes administering pregabalin or gabapentin and pain killer (avoiding opioids). I addition, muscle relaxant such as cyclobenzaprine can be also administered to improve sleep quality. In a high proportion of cases (around 42%), antidepressant with analgesic properties, namely duloxetine, is prescribed. In addition, usual care includes derivation to psychiatrist if needed.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Participants will be attended by a Medical Doctor that has a high level of expertise in fibromyalgia (rheumatologist or chronic pain specialist) at the Red Salud Christus, the most important private medical care network in Chile. In this clinic the protocol for the treatment of fibromyalgia includes administering pregabalin or gabapentin and pain killer (avoiding opioids). I addition, muscle relaxant such as cyclobenzaprine can be also administered to improve sleep quality. In a high proportion of cases (around 42%), antidepressant with analgesic properties, namely duloxetine, is prescribed. In addition, usual care includes derivation to psychiatrist if needed.
Study: NCT05372575

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PCV13 PAC study
Description: To test the serotype-specific IgG geometric mean concentration (GMC) and MOPA geometric mean titers (GMT) for each of the pneumococcal serotypes measured at the time of diagnosis of clinical pneumonia.
Study: NCT02275026

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging
Description: Diffusion tensor imaging
Study: NCT00486226

Intervention type: DEVICE
Intervention: Vascular Reconstruction Device
Description: CORDIS ENTERPRISE™ VRD
Study: NCT02538146

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: acetyl-L-carnitine 1000mg 2X per day for 3 months
Description: non-essential dietary amino acid
Study: NCT01819220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine/valsartan
Description: This is a phase IV clinical study. The study is a 24 week, prospective, randomized open labeled multicenter study to compare the efficacy of amlodipine/valsartan combination vs telmisartan/hydrochlorothiazide combination in reducing post prandial sugar. The study will be performed in hypertensive patients with metabolic syndrome.~Active group: Starting dose of amlodipine 5mg/ valsartan 80mg comparator group: Telmisartan 40mg/hydrochlorothiazide 12.5mg When the blood pressure is above the target goal of 140/90mmHg, up titration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.~When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide/telmisartan
Description: When the blood pressure is above the target goal of 140/90mmHg, uptitration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.~When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed.
Study: NCT02940886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside/ferric derisomaltose
Description: Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride (100 mL bags) and administered as a single IV infusion over approximately 20 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: Iron sucrose (Venofer®; 20 mg elemental iron/mL) was the comparator in this trial.~Iron sucrose was administered as 200 mg undiluted IV injections over approximately 2-5 minutes and repeated according to standard practice or physician choice up to a maximum of five times within the first two weeks starting at baseline. A cumulative dose of 1000 mg was recommended.
Study: NCT02221297

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Supplement product with plant stanol ester
Description: 2 grams plant stanols consumed with a meal daily for 3 to 4 weeks
Study: NCT03237260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Initiation: 300 mg at week 0, 2 and 6. Maintenance: Every 8 weeks after the sixth week at a fixed dose of 300 mg
Study: NCT00502905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 130 mg/m\^2 injected through the intravenous catheter over three hours, once a day, for four days, starting immediately after Fludarabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m\^2 through a central venous catheter over one hour, once a day, for four days.
Study: NCT03208192

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: liver transection during laparoscopic liver resection
Description: liver transection during laparoscopic liver resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: liver transection during laparoscopic liver resection
Description: liver transection during laparoscopic liver resection
Study: NCT00279903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (Btx-A)
Description: Participants randomized to Btx-A will be given either a low dose of 100 units or a high dose of 200 units. The Btx-A dose (100U or 200U) will be resonstituted with 4 cc of sterile non-preserved 0.9% sodium chloride solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (Btx-A)
Description: Participants randomized to Btx-A will be given either a low dose of 100 units or a high dose of 200 units. The Btx-A dose (100U or 200U) will be resonstituted with 4 cc of sterile non-preserved 0.9% sodium chloride solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortisone
Description: 1 cc of 40 mg/cc methylprednisolone will be drawn up in 22 gauge needles with 3 cc of sterile non-preserved 0.9% sodium chloride solution.
Study: NCT00022711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: 150 mg/m2/day Repeat cycles every 28 days following first daily dose of each cycle until toxicity or disease progression for a maximum of six months
Study: NCT02221297

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement product with plant stanol ester
Description: 2 grams plant stanols consumed with a meal daily for 3 to 4 weeks
Study: NCT01809990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavior Therapy
Study: NCT01818375

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goal Directed Fluid Therapy (GDFT)-Esophageal doppler guided

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard fluid therapy
Study: NCT01254604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative-Free Tafluprost or vehicle
Description: Preservative-free tafluprost (0.0015%) ophthalmic solution; Preservative-free vehicle ophthalmic solution (contains no active drug)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preservative-Free Timolol maleate
Description: Preservative-free timolol maleate (0.5%) ophthalmic solution
Study: NCT02295930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: folfoxiri+cetuximab+surgery+cetuximab
Description: Induction FOLFOXIRI plus cetuximab will consist of:~* CETUXIMAB 500 mg/sqm IV over 1-h\* , day 1 followed by~* IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~* l-LV 200 mg/sqm IV over 2-h, day 1 followed by~* 5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•CETUXIMAB 500 mg/sqm IV over 60-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: folfoxiri+cetuximab+surgery+bevacizumab
Description: Induction FOLFOXIRI plus cetuximab will consist of:~* CETUXIMAB 500 mg/sqm IV over 1-h\* , day 1 followed by~* IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~* l-LV 200 mg/sqm IV over 2-h, day 1 followed by~* 5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•BEVACIZUMAB 5 mg/kg IV over 30-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal.
Study: NCT01210950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cell and RPR injection
Description: mesenchymal cells and Plasma reach Protein are injected to the callus center
Study: NCT01008930

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HR PEM Scan
Description: PEMFlex Solo II, a high-resolution camera for PET scan imaging, on an area of body that has, or is suspected to have cancer following routine, standard, positron emission tomography/computed tomography (PET/CT) scan
Study: NCT01792986

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: water-only 24-hour fasting once per week for 6 weeks
Study: NCT02967848

Intervention type: OTHER
Intervention: 99mTc-mebrofenin hepatobiliary scintigraphy (HBS)
Description: 99mTc-mebrofenin HBS is a SPECT imaging procedure that allows evaluation of global and local liver function. Mebrofenin, bound to albumin, is taken up by hepatocytes in a similar manner to organic anions such as bilirubin. After hepatic uptake, the mebrofenin is excreted into the bile canaliculi. Dynamic imaging tools allow measurement of clearance rates for global function, and 3D SPECT imaging with corresponding CT allows visualisation of the local liver function with respect to anatomy. HBS allows direct visualisation of hepatocyte function.

Intervention type: OTHER
Intervention: Indocyanine Green
Description: ICG is a fluorescent dye injected into the patient. The dye is exclusively excreted by the liver. The ICG clearance rate is measured in the finger of the subject.

Intervention type: OTHER
Intervention: Liver Elasticity
Description: This is an Ultrasound measurement of the elasticity of the liver.
Study: NCT02158143

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Study: NCT00598533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapamycin + Probucol-eluting stent (ISAR stent)
Description: due to randomization, Rapamycin- + Probucol-eluting stent will be implanted

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polymer based Zotarolimus-eluting stent (Endeavor Resolute)
Description: due to randomization, Zotarolimus-eluting stent with polymer will be implanted
Study: NCT03378934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Berberine 200 mg twice daily for 4±1 weeks (Stage 1); then, 300 mg twice daily for 4±1 weeks (Stage 2); then, 400 mg twice daily for 4 weeks (Stage 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Standard treatment for 12±1 weeks.
Study: NCT04524936

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Study: NCT03568006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific passive mobilization
Description: Specific passive mobilizations for the shoulder
Study: NCT03378934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment for 12±1 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 100 mg once daily for 12±1 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100 mg once daily for 12±1 weeks.
Study: NCT03568006

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized treatment (standard protocol)
Description: Infrared rays, a program of therapeutic exercises and indications to improve their postural hygiene

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized treatment (standard protocol)
Description: Infrared rays, a program of therapeutic exercises and indications to improve their postural hygiene
Study: NCT03648996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fructose diet, isocaloric
Description: 6 month of consumption a low fructose diet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: 6 months of allopurinol treatment with the goal of decreasing uric acid compared to control group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 months of placebo treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fructose, hypocaloric
Description: 6 month of consumption a low fructose diet with a 500 Calorie/day energy restriction
Study: NCT03961919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine i.v. 30 mg/m²/d day -6 to -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARA-C
Description: Cytarabine i.v. 2 g/m²/d day -6 to -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: Treosulfan i.v. 10 g/m²/d day -6 to -4

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplant
Description: Autologous stem-cell transplantation i.v.: day 0 (source: peripheral blood)~Pegylated-Filgrastim s.c. 6 mg day +3
Study: NCT03454048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine (low dose)
Description: subcurative regimen (480 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine (low dose)
Description: subcurative regimen (480 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine (low dose)
Description: subcurative regimen (480 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine (low dose)
Description: subcurative regimen (480 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine (high dose)
Description: Curative regimen (960mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine (high dose)
Description: Curative regimen (960mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine pyrimethamine
Description: Curative regimen (1000mg/50mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine pyrimethamine
Description: Curative regimen (1000mg/50mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone Proguanil
Description: Curative regimen (1000/400 mg, for 3 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone Proguanil
Description: Curative regimen (1000/400 mg, for 3 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone Proguanil
Description: Curative regimen (1000/400 mg, for 3 days)
Study: NCT02841722

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ERIBULIN + G-CSF (Granulocyte-Colony Stimulating Factor)
Description: 8 additional blood samples
Study: NCT03454048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone Proguanil
Description: Curative regimen (1000/400 mg, for 3 days)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: malaria challenge infection, P. falciparum 3D7
Description: malaria challenge infection by P. falciparum 3D7-infected mosquito bites

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: malaria challenge infection, P. falciparum 3D7
Description: malaria challenge infection by P. falciparum 3D7-infected mosquito bites

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood stage malaria challenge infection, P. falciparum 3D7
Description: P. falciparum 3D7-infected human erythrocytes administered intravenously for the purpose controlled human malaria infection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood stage malaria challenge infection, P. falciparum 3D7
Description: P. falciparum 3D7-infected human erythrocytes administered intravenously for the purpose controlled human malaria infection.
Study: NCT01713036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Part A: Subjects will receive unlabeled pimasertib capsules orally at a single dose of 60 milligram (mg) on Day 1. One hour after administration of the oral unlabeled pimasertib dose, the intravenous (IV) tracer dose of 9 kilobecquerel (kBq) \[14C\] pimasertib will be administered as a bolus injection. On Days 3-21 (except Day 8), subjects will receive unlabeled pimasertib capsules orally at a dose of 60 mg twice daily (BID). In the morning of Day 8, subjects will receive 60 mg unlabeled pimasertib capsules spiked with a dose of 2.6 megabecquerel (MBq) (70 microcuries \[mcgCi\]) of \[14C\] pimasertib orally. In the evening of Day 8, subjects will receive the evening dose of 60 mg pimasertib as unlabeled pimasertib capsules orally. Part B : Subjects will be administered with 60 mg BID unlabeled pimasertib as oral capsules continuously in cycles of 21 days until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow-up or death.
Study: NCT03378934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once daily for 12±1 weeks.
Study: NCT03533478

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral treatment Alzer y Diamel
Description: Alzer:~Administration way: Oral Dosage: one 500 mg tablet 3 times a day (1500 mg daily) Frequency: after breakfast, lunch and dinner. Duration: one year.~Diamel:~Administration way: Oral Dosage: two 660mg capsules 3 times a day (3960 mg daily) Frequency: before breakfast, lunch and dinner. Duration: one year.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment
Study: NCT04328623

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: conversational hypnosis technique call the magic glove

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infiltration
Description: Ultrasound-guided hand infiltration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infiltration
Description: Ultrasound-guided hand infiltration
Study: NCT01278680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives for walkstation usage
Description: The investigators are testing the effect of two different incentive schemes on people's usage of walkstations at work: either a personal incentive (in which people receive personal financial benefit for using the walkstations) vs. a charitable incentive (in which others receive financial benefit if a given individual uses the walkstation).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incentives for walkstation usage
Description: The investigators are testing the effect of two different incentive schemes on people's usage of walkstations at work: either a personal incentive (in which people receive personal financial benefit for using the walkstations) vs. a charitable incentive (in which others receive financial benefit if a given individual uses the walkstation).
Study: NCT01127425

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic colonic resection
Description: Conventional surgery compared to laparoscopic sigmoid resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic sigmoid resection
Description: sigmoid resection by laparoscopic surgery